Coffee prevents early events in tamoxifen-treated breast cancer patients and modulates hormone receptor status

Cancer Causes and Control

Volumn 24, Issue 5, 2013, Pages 929-940

  Simonsson, Maria ^a   Söderlind, Viktoria ^a   Henningson, Maria ^a,b   Hjertberg, Maria ^a,c   Rose, Carsten ^d   Ingvar, Christian ^e   Jernström, Helena ^a  

^a LUND UNIVERSITY   (Sweden)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^c VRINNEVI HOSPITAL   (Sweden)

^d Division of Cancer and Hematology   (Sweden)

^e UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Breast cancer; Coffee; CYP1A2; CYP2C8; Estrogen receptor; Progesterone receptor

Indexed keywords

CYTOCHROME P450 1A2; CYTOCHROME P450 2C8; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER PREVENTION; CANCER RISK; COFFEE; CONTROLLED STUDY; CYP1A2 GENE; CYP2C8 GENE; DISEASE ASSOCIATION; FEMALE; FOOD INTAKE; GENOTYPE; HORMONE METABOLISM; HUMAN; LIFESTYLE; MAJOR CLINICAL STUDY; ONCOGENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUESTIONNAIRE; SWEDEN;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; ARYL HYDROCARBON HYDROXYLASES; BREAST NEOPLASMS; COFFEE; CYTOCHROME P-450 CYP1A2; FEMALE; FOOD-DRUG INTERACTIONS; GENOTYPE; HUMANS; MIDDLE AGED; RECEPTORS, ESTROGEN; TAMOXIFEN;

EID: 84892794443     PISSN: 09575243     EISSN: 15737225     Source Type: Journal    
DOI: 10.1007/s10552-013-0169-1     Document Type: Article

References (45)

1. The National Board of Health and Welfare (2011) Cancer incidence in Sweden 2010. http://www.socialstyrelsen.se/Lists/Artikelkatalog/Attachments/ 18530/2011-12-15.pdf
2. Fernö M, Borg A , Johansson U, Norgren A, Olsson H, Ryden S, Sellberg G (1990) Estrogen and progesterone receptor analyses in more than 4,000 human breast cancer samples. A study with special reference to age at diagnosis and stability of analyses. Southern Swedish Breast Cancer Study Group. Acta Oncol 29(2):129-135
3. Larsson SC, Bergkvist L, Wolk A (2009) Coffee and black tea consumption and risk of breast cancer by estrogen and progesterone receptor status in a Swedish cohort. Cancer Causes Control 20(10):2039-2044. doi:10.1007/s10552-009- 9396-x
4. Conzen SD (2008) Minireview: nuclear receptors and breast cancer. Mol Endocrinol 22(10):2215-2228. doi:10.1210/me.2007-0421
5. Osborne CK, Schiff R (2011) Mechanisms of endocrine resistance in breast cancer. Annu Rev Med 62:233-247. doi:10.1146/annurev-med-070909-182917
6. Li J, Seibold P, Chang-Claude J, Flesch-Janys D, Liu J, Czene K, Humphreys K, Hall P (2011) Coffee consumption modifies risk of estrogen-receptor negative breast cancer. Breast Cancer Res 13(3):R49. doi:10.1186/bcr2879
7. The European Coffee Federation (2010) The European coffee report, vol 2011. The European Coffee Federation. http://www.scribd.com/doc/45025346/ European-Coffee-Report-2009
8. Allred KF, Yackley KM, Vanamala J, Allred CD (2009) Trigonelline is a novel phytoestrogen in coffee beans. J Nutr 139(10):1833-1838. doi:10.3945/jn.109.108001
9. Michels KB, Holmberg L, Bergkvist L, Wolk A (2002) Coffee, tea, and caffeine consumption and breast cancer incidence in a cohort of Swedish women. Ann Epidemiol 12(1):21-26
10. Freedman ND, Park Y, Abnet CC, Hollenbeck AR, Sinha R (2012) Association of coffee drinking with total and cause-specific mortality. N Engl J Med 366(20):1891-1904. doi:10.1056/NEJMoa1112010
11. Svenska bröstcancergruppen (2011) Nationella riktlinjer 2011, vardprogram. http://www.swebcg.se/Files/Docs/Nationella-riktlinjer 110131.pdf. Accessed 20110512 2011
12. Jordan VC, Koerner S (1975) Tamoxifen (ICI 46,474) and the human carcinoma 8S oestrogen receptor. Eur J Cancer 11(3): 205-206
13. Jin Y, Desta Z, Stearns V, Ward B, Ho H, Lee KH, Skaar T, Storniolo AM, Li L, Araba A, Blanchard R, Nguyen A, Ullmer L, Hayden J, Lemler S, Weinshilboum RM, Rae JM, Hayes DF, Flockhart DA (2005) CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 97(1):30-39. doi:10.1093/jnci/dji005
14. Dunn BK, Greene MH, Kelley JM, Costantino JP, Clifford RJ, Hu Y, Tang G, Kazerouni N, Rosenberg PS, Meerzaman DM, Buetow KH (2010) Novel pathway analysis of genomic polymorphism-cancer risk interaction in the breast cancer prevention trial. Int J Mol Epidemiol Genet 1(4):332-349
15. Chen J, Halls SC, Alfaro JF, Zhou Z, Hu M (2004) Potential beneficial metabolic interactions between tamoxifen and isoflavones via cytochrome P450-mediated pathways in female rat liver microsomes. Pharm Res 21(11):2095-2104
16. Andersson H, Helmestam M, Zebrowska A, Olovsson M, Brittebo E (2010) Tamoxifen-induced adduct formation and cell stress in human endometrial glands. Drug Metab Dispos 38(1):200-207. doi:10.1124/dmd.109.029488
17. Kot M, Daniel WA (2008) The relative contribution of human cytochrome P450 isoforms to the four caffeine oxidation pathways: an in vitro comparative study with cDNA-expressed P450 s including CYP2C isoforms. Biochem Pharmacol 76(4):543-551. doi:10.1016/j.bcp.2008.05.025
18. Bageman E, Ingvar C, Rose C, Jernström H (2008) Coffee consumption and CYP1A2.*1F genotype modify age at breast cancer diagnosis and estrogen receptor status. Cancer Epidemiol Biomarkers Prev 17(4):895-901. doi:10.1158/1055-9965.EPI-07-0555
19. Sachse C, Brockmoller J, Bauer S, Roots I (1999) Functional significance of a C-[A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. Br J Clin Pharmacol 47(4):445-449
20. Djordjevic N, Ghotbi R, Jankovic S, Aklillu E (2010) Induction of CYP1A2 by heavy coffee consumption is associated with the CYP1A2 -163C[A polymorphism. Eur J Clin Pharmacol 66(7):697-703. doi:10.1007/s00228-010-0823-4
21. Jernström H, Bageman E, Rose C, Jönsson PE, Ingvar C (2009) CYP2C8 and CYP2C9 polymorphisms in relation to tumour characteristics and early breast cancer related events among 652 breast cancer patients. Br J Cancer 101(11):1817-1823. doi: 10.1038/sj.bjc.6605428
22. Ringberg A, Bageman E, Rose C, Ingvar C, Jernström H (2006) Of cup and bra size: reply to a prospective study of breast size and premenopausal breast cancer incidence. Int J Cancer 119(9):2242-2243. Author reply 2244. doi:10.1002/ijc.22104
23. Osborne CK, Yochmowitz MG, Knight WA 3rd, McGuire WL (1980) The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer 46(12 Suppl):2884-2888
24. Cui X, Schiff R, Arpino G, Osborne CK, Lee AV (2005) Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy. J Clin Oncol 23(30):7721-7735. doi: 10.1200/JCO.2005.09.004
25. Bardou VJ, Arpino G, Elledge RM, Osborne CK, Clark GM (2003) Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J Clin Oncol 21(10):1973-1979. doi:10.1200/JCO.2003.09.099
26. Hashimoto T, He Z, Ma WY, Schmid PC, Bode AM, Yang CS, Dong Z (2004) Caffeine inhibits cell proliferation by G0/G1 phase arrest in JB6 cells. Cancer Res 64(9):3344-3349
27. Cui X, Zhang P, Deng W, Oesterreich S, Lu Y, Mills GB, Lee AV (2003) Insulin-like growth factor-I inhibits progesterone receptor expression in breast cancer cells via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway: progesterone receptor as a potential indicator of growth factor activity in breast cancer.Mol Endocrinol 17(4):575-588. doi:10.1210/me.2002-0318
28. Divekar SD, Storchan GB, Sperle K, Veselik DJ, Johnson E, Dakshanamurthy S, Lajiminmuhip YN, Nakles RE, Huang L, Martin MB (2011) The role of calcium in the activation of estrogen receptor-Alpha. Cancer Res 71(5):1658-1668. doi: 10.1158/0008-5472.CAN-10-1899
29. Caldarella A, Crocetti E, Bianchi S, Vezzosi V, Urso C, Biancalani M, Zappa M (2011) Female breast cancer status according to ER, PR and HER2 expression: a population based analysis. Pathol Oncol Res. doi:10.1007/s12253- 011-9381-z
30. Jernström H, Klug TL, Sepkovic DW, Bradlow HL, Narod SA (2003) Predictors of the plasma ratio of 2-hydroxyestrone to 16alpha-hydroxyestrone among pre-menopausal, nulliparous women from four ethnic groups. Carcinogenesis 24(5):991-1005
31. Bradlow HL, Jernström H, Sepkovic DW, Klug TL, Narod SA (2006) Comparison of plasma and urinary levels of 2-hydroxyestrogen and 16 alpha-hydroxyestrogen metabolites. Mol Genet Metab 87(2):135-146. doi:10.1016/j.ymgme.2005.08.001
32. Klug TL, Bageman E, Ingvar C, Rose C, Jernström H (2006) Moderate coffee and alcohol consumption improves the estrogen metabolite profile in adjuvant treated breast cancer patients: a pilot study comparing pre-And post-operative levels. Mol Genet Metab 89(4):381-389. doi:10.1016/j.ymgme.2006. 08.005
33. Schneider J, Huh MM, Bradlow HL, Fishman J (1984) Antiestrogen action of 2-hydroxyestrone on MCF-7 human breast cancer cells. J Biol Chem 259(8):4840-4845
34. Telang NT, Suto A, Wong GY, Osborne MP, Bradlow HL (1992) Induction by estrogen metabolite 16 alpha-hydroxyestrone of genotoxic damage and aberrant proliferation in mouse mammary epithelial cells. J Natl Cancer Inst 84(8):634-638
35. Thibodeau PA, Bissonnette N, Bedard SK, Hunting D, Paquette B (1998) Induction by estrogens of methotrexate resistance in MCF-7 breast cancer cells. Carcinogenesis 19(9):1545-1552
36. Lee AJ, Cai MX, Thomas PE, Conney AH, Zhu BT (2003) Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology 144(8):3382-3398
37. Berthou F, Flinois JP, Ratanasavanh D, Beaune P, Riche C, Guillouzo A (1991) Evidence for the involvement of several cytochromes P-450 in the first steps of caffeine metabolism by human liver microsomes. Drug Metab Dispos 19(3):561-567
38. Bahadur N, Leathart JB, Mutch E, Steimel-Crespi D, Dunn SA, Gilissen R, Houdt JV, Hendrickx J, Mannens G, Bohets H, Williams FM, Armstrong M, Crespi CL, Daly AK (2002) CYP2C8 polymorphisms in Caucasians and their relationship with paclitaxel 6alpha-hydroxylase activity in human liver microsomes. Biochem Pharmacol 64(11):1579-1589
39. Larsson SC, Giovannucci E, Wolk A (2006) Coffee consumption and stomach cancer risk in a cohort of Swedish women. Int J Cancer 119(9):2186-2189. doi:10.1002/ijc.22105
40. Jernström H, Frenander J, Fernö M, Olsson H (1999) Hormone replacement therapy before breast cancer diagnosis significantly reduces the overall death rate compared with never-use among 984 breast cancer patients. Br J Cancer 80(9):1453-1458. doi: 10.1038/sj.bjc.6690543
41. Schuetz F, Diel IJ, Pueschel M, von Holst T, Solomayer EF, Lange S, Sinn P, Bastert G, Sohn C (2007) Reduced incidence of distant metastases and lower mortality in 1072 patients with breast cancer with a history of hormone replacement therapy. Am J Obstet Gynecol 196(4):342 e341-349. doi:10.1016/j.ajog. 2006.10.901
42. Nanda K, Bastian LA, Schulz K (2002) Hormone replacement therapy and the risk of death from breast cancer: a systematic review. Am J Obstet Gynecol 186(2):325-334
43. Stahlberg C, Lynge E, Andersen ZJ, Keiding N, Ottesen B, Rank F, Hundrup YA, Obel EB, Pedersen AT (2005) Breast cancer incidence, case-fatality and breast cancer mortality in Danish women using hormone replacement therapy-A prospective observational study. Int J Epidemiol 34(4):931-935. doi:10.1093/ije/dyi103
44. Chlebowski RT, Anderson GL, Gass M, Lane DS, Aragaki AK, Kuller LH, Manson JE, Stefanick ML, Ockene J, Sarto GE, Johnson KC, Wactawski-Wende J, Ravdin PM, Schenken R, Hendrix SL, Rajkovic A, Rohan TE, Yasmeen S, Prentice RL (2010) Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA 304(15):1684-1692. doi:10.1001/jama.2010.1500
45. Markkula A, Hietala M, Henningson M, Ingvar C, Rose C, Jernstro ̈m H (2012) Clinical profiles predict early nonadherence to adjuvant endocrine treatment in a prospective breast cancer cohort. Cancer Prev Res (Phila) 5(5):735-745. doi:10.1158/1940-6207. CAPR-11-0442